Area of research
Infectious Diseases · Virology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, HIV Research and Treatment, Monoclonal and Polyclonal Antibodies Research, and vaccines and immunoinformatics approaches.
Antigen affinity and site of immunization dictate B cell recall responses
Spike deep mutational scanning helps predict success of SARS-CoV-2 clades
Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies
Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2
Optimized SMRT-UMI protocol produces highly accurate sequence datasets from diverse populations—Application to HIV-1 quasispecies
SARS-CoV-2 evolution in the Omicron era
Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses
Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level
Phenotypic characterization of single CD4+ T cells harboring genetically intact and inducible HIV genomes
Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study
Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages
Frequent use of IGHV3-30-3 in SARS-CoV-2 neutralizing antibody responses
Selection Analysis Identifies Clusters of Unusual Mutational Changes in Omicron Lineage BA.1 That Likely Impact Spike Function
Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study
A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
Evasion of neutralising antibodies by omicron sublineage BA.2.75
Immunoglobulin germline gene polymorphisms influence the function of SARS-CoV-2 neutralizing antibodies
Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies
Longitudinal single-cell analysis of SARS-CoV-2–reactive B cells uncovers persistence of early-formed, antigen-specific clones
The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages
Rhesus and cynomolgus macaque immunoglobulin heavy-chain genotyping yields comprehensive databases of germline VDJ alleles
Single-cell analysis pinpoints distinct populations of cytotoxic CD4 <sup>+</sup> T cells and an IL-10 <sup>+</sup> CD109 <sup>+</sup> T <sub>H</sub> 2 cell population in nasal polyps
SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses
Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice
RDP5: a computer program for analyzing recombination in, and removing signals of recombination from, nucleotide sequence datasets
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2
Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells